Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-05-30
2011-11-22
Dahle, Chun (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388220, C530S388700, C530S388730, C424S130100, C424S133100, C424S141100, C424S142100, C424S143100, C424S144100, C424S152100, C424S155100, C424S172100, C424S174100
Reexamination Certificate
active
08063187
ABSTRACT:
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen et al.
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5264586 (1993-11-01), Nicolaou et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5712374 (1998-01-01), Kuntsmann et al.
patent: 5714586 (1998-02-01), Kunstmann et al.
patent: 5773001 (1998-06-01), Hamann et al.
patent: 5804396 (1998-09-01), Plowman et al.
patent: 6403312 (2002-06-01), Dahiyat et al.
patent: 6602684 (2003-08-01), Umana et al.
patent: 6737056 (2004-05-01), Presta et al.
patent: 6797492 (2004-09-01), Daugherty et al.
patent: 6821505 (2004-11-01), Ward et al.
patent: 7083784 (2006-08-01), Dall'Acqua et al.
patent: 7117096 (2006-10-01), Luo et al.
patent: 7129261 (2006-10-01), Ng et al.
patent: 7217797 (2007-05-01), Hinton et al.
patent: 7217798 (2007-05-01), Hinton et al.
patent: 7315786 (2008-01-01), Dahiyat et al.
patent: 7335742 (2008-02-01), Presta et al.
patent: 7361740 (2008-04-01), Hinton et al.
patent: 7365168 (2008-04-01), Hinton et al.
patent: 7371826 (2008-05-01), Presta et al.
patent: 2002/0048772 (2002-04-01), Dahiyat et al.
patent: 2002/0119492 (2002-08-01), Chirino et al.
patent: 2003/0003097 (2003-01-01), Reff et al.
patent: 2003/0130827 (2003-07-01), Desjarlais et al.
patent: 2003/0157108 (2003-08-01), Presta et al.
patent: 2004/0110226 (2004-06-01), Lazar et al.
patent: 2004/0230380 (2004-11-01), Chirino et al.
patent: 2005/0118174 (2005-06-01), Presta et al.
patent: 2005/0249723 (2005-11-01), Lazar et al.
patent: 2006/0008883 (2006-01-01), Lazar et al.
patent: 2006/0067930 (2006-03-01), Adams et al.
patent: 2006/0134105 (2006-06-01), Lazar et al.
patent: 2006/0148009 (2006-07-01), Barbosa et al.
patent: 2006/0173170 (2006-08-01), Chamberlain et al.
patent: 2006/0198840 (2006-09-01), Dall'Acqua et al.
patent: 2006/0233791 (2006-10-01), Tedder et al.
patent: 2007/0135620 (2007-06-01), Chamberlain et al.
patent: 2007/0231329 (2007-10-01), Lazar et al.
patent: 2008/0260731 (2008-10-01), Bernett et al.
patent: WO 81/01145 (1981-04-01), None
patent: WO 88/07378 (1988-10-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 93/21232 (1993-10-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33978 (1996-10-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/38731 (1997-10-01), None
patent: WO 97/38983 (1997-10-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 99/06378 (1999-02-01), None
patent: WO 99/06396 (1999-02-01), None
patent: WO 99/09016 (1999-02-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 01/29246 (2001-04-01), None
patent: WO 01/59066 (2001-08-01), None
patent: WO 02/30954 (2002-04-01), None
patent: WO 02/31140 (2002-04-01), None
patent: WO 02/060919 (2002-08-01), None
patent: WO 03/014325 (2003-02-01), None
patent: WO 2004/004798 (2004-01-01), None
patent: WO 2004/035752 (2004-04-01), None
patent: WO 2004/091658 (2004-10-01), None
patent: WO 2004/092219 (2004-10-01), None
patent: WO 2005/037867 (2005-04-01), None
patent: WO 2005/047327 (2005-05-01), None
patent: WO 2006-019447 (2006-02-01), None
patent: WO 2006/019447 (2006-02-01), None
patent: WO 2006/031370 (2006-03-01), None
patent: WO 2006/047350 (2006-05-01), None
patent: WO 2006/053301 (2006-05-01), None
patent: WO 2006/105338 (2006-10-01), None
patent: WO 2006/133450 (2006-12-01), None
Meeker, et al. “A uniquie human B lymphocyte antigen defined by a monoclonal antibody” Hybridoma, 1984, 305-320, vol. 3, No. 4.
Heyman, et al. “Feedback regulation by IgG antibodies” Immuno Ltrs., 2003, 157-161, vol. 88, No. 2.
Nimmerjahn, et al. “Fc gamma receptors: Old friends and new family members” Immunity, 2006, 19-28, vol. 24, No. 1.
Shields, et al, “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcyR” J. Biological Chem., 2001, 6591-6604, vol. 276, No. 9.
Chu, et al., “Conengagement of BCR coreceptor CD19 and inhibitory Fc receptor γRIIb suppresses B cell function: a potential therapeutic strategy for autoimmune disease” Internet Citation, 2008, www. Xencor.com.
Zhukovsky, et al.“Xmab 5574: an FC engineered anti CD-19 monoclonal antibody with in vitro and in vivo efficacy against Lymphoma and Leukemia” Internet Citation, www.Xencor.com, 2008.
Mihaylova, et al. “Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor” International Immunol., 2008, 165-175, vol. 20, No. 2.
Tchorbanov, et al. “Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/Ipr mice” European J. Immuno., 2007, 3587-3596, vol. 37, No. 12.
Veri, et al., “Monoclonal antibodies capable of discriminating the human inhibitory Fc gamma-receptor IIB (CD32B) from the activiatin Fc gamma-receptor IIA (CD32A): biochemical, biological, and functional characterization” Immunology, 2007, 392-404, vol. 121, No. 3.
Chu, et al., “Inhibition of B cell receptor-mediated activation of primary human B cells by conengagement of CD19 and FcγRIIb with Fc-engineered antibodies” Molecular Immunology, 2008, 3926-3933, vol. 45, No. 15.
Amigorena, et al., “Cytoplasmic domain heterogeneity and functions of IgG receptors in B lymphocytes” Science, (1992), 1808-1812, vol. 256, No. 5065.
Ashkenazi, et al “Immunoadhesins as research toolls and therapeutic agents” Curr. Opin in Immunol, 1997, 195-200, vol. 9.
Atwell, et al.“Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library” J. Mol. Biol, 1997, 26-35, vol. 270.
Beigier-Bompadre, et al “The Formyl Peptide N-Fornyl-methionly-leucyl-phenylalanine Downregulates the Expression of FcyRs in Interferon-y-Activated Monocytes/Macrophages In Vitro and In Vivo” Scand. J. Immunol., 2003, 221-228, vol. 57.
Binstadt, et al “IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy” J. Allergy and Clinical Immuno., (2003), 697-703, vol. 111, No. 4.
Bitonti, et al “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway” Proc. Natl. Acad. Sci., 2004, 9763-9768, vol. 101.
Blank, et al “Decreased transcription of the human FCGR2B gene mediated by the—343G/C promoter polymorphsm and association with systemic lupus erythematosus” Human Genetics, 2005, 220-227, vol. 117, No. 2.
Bruggemann, et al “Production of human antibody repertoires in transgenic mice” Current Opinion in Biotech., 1997, 455-458, vol. 8.
Campbell (Stanley) et al “A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GIcNAc:Glycopeptide beta-4-N-acetylglucosaminyltransferase III activity” J. Biol. Chem., 1984, 13370-13378, vol. 259, No. 21.
Caron, et al “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies” J. Exp. Med., 1992, 1191-1195, vol. 176.
Carter, et al., “Bispecific human IgG by design” J. Immunol. Methods, 2001, 7-15, vol. 248.
Carter, et al., “Potent antibody therapeutics by design” Nature Reviews, 2006, 343-357, vol. 6.
Carton, et al “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcyRIIIa gene” Blood, 2002, vol. 99, No. 3.
Chamow, et al, “Immunoadhesins : principles and applications” Tr
Chu Seung Yup
Desjarlais John R.
Karki Sher Bahadur
Lazar Gregory Alan
Moore Gregory L.
Dahle Chun
Dorsey & Whitney LLP
Xencor, Inc.
LandOfFree
Methods and compositions for inhibiting CD32B expressing cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting CD32B expressing cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting CD32B expressing cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278794